PD-L1 Targeting Compounds for HBV and HDV Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for PD-L1 related diseases such as liver diseases, cancer, hepatocellular carcinoma, viral diseases, and hepatitis B are inadequate, with limited efficacy and tolerability, and there is a need for more effective therapies that target the PD-1/PD-L1 pathway to enhance immune response and inhibit viral replication.
Innovation Solution
Development of compounds that inhibit PD-1/PD-L1 interaction, including pharmaceutical compositions containing these compounds, to treat PD-L1 related diseases by administering them to subjects or contacting infected cells, thereby inhibiting HBV and HDV replication and enhancing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for PD-L1 related diseases are used, then disease management is maintained, but efficacy and tolerability are limited
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of PD-1/PD-L1 interaction inhibitors through various substituents (R1a-R4, Y1a-Y2b) to optimize both efficacy and tolerability. The compounds represent systematic variations in molecular parameters including ring structures, substituent positions, and chemical groups to achieve improved therapeutic profiles
2Reliability
If PD-1/PD-L1 pathway targeting is enhanced to improve immune response, then antiviral efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent extracts and isolates the specific PD-1/PD-L1 interaction mechanism as the primary therapeutic target, developing compounds that specifically inhibit this pathway. This focused approach on a single molecular interaction simplifies the treatment mechanism compared to broader immunomodulatory approaches while maintaining enhanced immune response efficacy
3Productivity
If viral replication inhibition is strengthened, then disease progression is slowed, but off-target effects may increase
Solution Approach 1:
The patent uses the PD-1/PD-L1 interaction as an intermediary target to indirectly control viral replication. Rather than directly targeting viral replication machinery, the compounds mediate immune system activation through PD-1/PD-L1 inhibition, which then suppresses viral replication. This indirect approach reduces off-target effects compared to direct antiviral mechanisms
Data Source
AI summary
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.